HER2-(Ultra)Low Expressing Breast Cancer
1 clinical trials · Condition
◉ Watch HER2-(Ultra)Low Expressing Breast Cancer
| Record | Firm | Date |
|---|---|---|
| DESTINY Breast Respond HER2-(Ultra)Low Europe (NCT05945732) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-10-24 |
Track HER2-(Ultra)Low Expressing Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.